ARCT
Arcturus Therapeutics Holdings Inc.
There isn't enough reported data to score ARCT yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ARCT Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
ARCT's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ARCT PE Valuation
ARCT has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ARCT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect ARCT's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ARCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.10 | -$0.65 |
| Q2 2026 | -$3.33 | -$1.11 |
| Q1 2026 | -$2.83 | -$0.31 |
| Q4 2025 | -$2.40 | +$0.60 |
| Q3 2025 | -$2.45 | -$0.15 |
| Q2 2025 | -$2.22 | +$0.43 |
| Q1 2025 | -$2.52 | +$1.47 |
| Q4 2024 | -$3.00 | -$1.88 |
ARCT is still losing money, but far less than before: $3.10 per share over the past year, against $7.74 at its worst in late 2021.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ARCT on earnings quality, reporting a profit while its opponent remains loss making.
ARCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.3M | +6.7% |
| Q2 2026 | $3M | -90% |
| Q1 2026 | $2.1M | -93% |
| Q4 2025 | $7.2M | -68% |
| Q3 2025 | $17.2M | -59% |
| Q2 2025 | $28.3M | -43% |
| Q1 2025 | $29.4M | -23% |
| Q4 2024 | $22.8M | -26% |
ARCT's revenue is recovering but still below its 2022 peak: $18M last quarter, up 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -50% | +46 points |
| Q2 2026 | -863% | -822 points |
| Q1 2026 | -1404% | -1347 points |
| Q4 2025 | -435% | -288 points |
| Q3 2025 | -96% | -71 points |
| Q2 2025 | -41% | +1.3 points |
| Q1 2025 | -57% | +23 points |
| Q4 2024 | -147% | -88 points |
ARCT's operating margin was −50% last quarter, up 46 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ARCT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ARCT on profitability, with a higher operating margin.
ARCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7M | +$10.4M |
| Q2 2026 | -$19.9M | -$14.2M |
| Q1 2026 | -$19.4M | +$15.8M |
| Q4 2025 | -$16.1M | -$15.9M |
| Q3 2025 | -$17.3M | +$6.5M |
| Q2 2025 | -$5.8M | +$24.7M |
| Q1 2025 | -$35.3M | -$29.5M |
| Q4 2024 | -$284K | +$1.2M |
ARCT has burned cash in almost every quarter: −$62M over the past year, against −$59M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ARCT on cash generation, producing positive trailing cash flow while its opponent burns cash.
ARCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +17K shares |
| 1 year | +4.6% | +1.3M shares |
| 3 years | +5% | +1.3M shares |
| 5 years | +14% | +3.6M shares |
ARCT has 28M diluted shares, up 4.6% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ARCT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ARCT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2023 | -4.6x | Net Cash |
| Q4 2022 | -24.1x | Net Cash |
ARCT has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ARCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.7 | Neutral |
| Stochastic | 31.9 | Neutral |
ARCT's weekly RSI is 44 (neutral) and its Stochastic is 32 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ARCT PE vs Healthcare Sector
| Metric | ARCT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ARCT has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ARCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.3 | 26% below |
| 20 week MA | $10.7 | 21% below |
| 50 week MA | $8.73 | 3.3% below |
| 100 week MA | $11.6 | 27% below |
| 200 week MA | $18.8 | 55% below |
ARCT is in a downtrend: it's below all five of its weekly moving averages, and 55% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ARCT on trend strength, trading above more of its moving averages.
ARCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.5 | $98.1 | +756% |
| 2021 | $98.1 | $39.9 | -59% |
| 2022 | $39.9 | $17.3 | -57% |
| 2023 | $17.3 | $31.5 | +83% |
| 2024 | $31.5 | $17.0 | -46% |
| 2025 | $17.0 | $6.16 | -64% |
| 2026 YTD | $6.16 | $8.44 | +37% |
ARCT has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.